| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe24c92327a3f85d7bd135fc4a6545cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eb2ce78fcbf236c29e89e706f15b554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b64bdc8d4cedfb51aabd9444260f0191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c5d6693511f4c2ecf1ede446e4c9f26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e755a13473d82a70819f0d375fa0fcee |
| publicationDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2395799-T3 |
| titleOfInvention |
Genetically modified alpha V anti- integrin hybrid antibodies |
| abstract |
A genetically modified recombinant anti-integrin αv hybrid antibody, comprising (i) the CDR regions of the light chain: CDR1: RASQDISNYLA CDR2: YTSKIHS CDR3: QQGNTFPYT (ii) the CDR regions of the heavy chain: CDR1: SFWMH, CDR2: YINPRSGYTEYNEIFRD, CDR3: FLGRGAMDY; (Iii) the light chain framework regions: FR1: DIQMTQSPSSLSASVGDRVTITC, FR2: WYQQKPGKAPKLLIY FR3: GVPSRFSGSGSGTDYTFTISSLQPEDIATYYC FR-4: FGQGTKVEIK (iv) the frame FR1 heavy chain regions: QVQLQQSGAELAEPGASVKMSCKASGYTFS FR2: WVKQRPGQGLEWIG FR3: KATMTADTSSSTAYMQLSGLTSEDSAVYYCAS FR4: WGQGTSVTVSS and (v) a constant region of the heavy chain that is derived from human IgG and a region of human constant light chain. |
| priorityDate |
2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |